deucravacitinib vs Envudeucitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

deucravacitinib · Sotyktu

Marketed by Bristol-Myers Squibb

Approved in Psoriasissmall molecule
Reliable signal

NCT03611751 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo- and active-controlled trial of 1,020 participants. Both primary clinical endpoints at week 16 were met: deucravacitinib produced significantly more participants with sPGA 0/1 and PASI 75 responses than placebo.

Next expected readout: November 2026 · NCT05570955 (registry estimate)

Reported efficacy

The Percentage of Participants With sPGA Response of 0 or 1 (At week 16); The Percentage of Participants With PASI 75 Response (At week 16): The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5) (met)

Result source: NCT04167462

Envudeucitinib

Developed by Alumis and partners

Phase 3 in Psoriasissmall molecule
Reliable signal

NCT06586112 · Phase 3 · completed

Participants were randomized and blinded across drug, placebo, and active-comparator arms. A much larger share of patients on envudeucitinib achieved high levels of skin clearance than on placebo, with a highly significant difference.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2027 · NCT05739435 (registry estimate)

Reported efficacy

To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo (16 weeks): PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all) (met)

Result source: NCT06586112

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdeucravacitinibEnvudeucitinib
PASI 7553% vs 9.4%+43.6 vs placebowk 16 · n 511NCT03611751
9 other results
  • 58.4% vs 12.7% wk 16 · n 332 · Phase 3 · primary NCT03624127
  • 68.8% vs 8.1% wk 16 · n 144 · Phase 3 · primary NCT04167462
  • 53% vs 39.8% wk 16 · n 511 · Phase 3 · secondary NCT03611751
  • 58.4% vs 35.1% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 75% vs 6.7% 12 mg QD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 66.7% vs 6.7% 6 mg BID · wk 12 · n 45 · Phase 2 · primary NCT02931838
  • 9.1% vs 6.7% 3 mg QOD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 38.6% vs 6.7% 3 mg QD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 68.9% vs 6.7% 3 mg BID · wk 12 · n 45 · Phase 2 · primary NCT02931838
56.4% vs 0%+56.4 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 64.1% vs 0% 40mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 33.3% vs 0% 20mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
  • 56.4% vs 0% 20mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 19.4% vs 0% 10mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
PASI 9027% vs 2.7%+24.3 vs placebowk 16 · n 511NCT03611751
2 other results
  • 35.5% vs 4.2% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 38.2% vs 1.4% wk 16 · n 144 · Phase 3 · secondary NCT04167462
—Not posted · NCT06588738
PASI 10010.2% vs 1.2%+9 vs placebowk 16 · n 511NCT03611751
2 other results
  • 14.2% vs 0.6% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 4.2% vs 0% wk 16 · n 144 · Phase 3 · secondary NCT04167462
—Not posted · NCT06588738
sPGA 0/149.5% vs 8.6%+40.9 vs placebowk 16 · n 511NCT03611751
11 other results
  • 53.6% vs 7.2% wk 16 · n 332 · Phase 3 · primary NCT03624127
  • 55.6% vs 6.8% wk 16 · n 144 · Phase 3 · primary NCT04167462
  • 49.5% vs 33.9% wk 16 · n 511 · Phase 3 · secondary NCT03611751
  • 53.6% vs 32.1% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 75% vs 6.7% 12 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 64.4% vs 6.7% 6 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • 20.5% vs 6.7% 3 mg QOD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 38.6% vs 6.7% 3 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 75.6% vs 6.7% 3 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • 35.5% vs 8.2% wk 16 · n 107 · Phase 4 · secondary NCT05701995
  • 51% vs 4.3% wk 16 · n 96 · Phase 4 · secondary NCT05478499
53.8% vs 7.9%+45.9 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 59% vs 7.9% 40mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 38.9% vs 7.9% 20mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
  • 48.7% vs 7.9% 20mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 16.7% vs 7.9% 10mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
DLQI, change-10.2 vs -2.9−7.3 vs placebo12 mg QD · wk 12 · n 44NCT02931838
4 other results
  • -8.4 vs -2.9 6 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • -3.8 vs -2.9 3 mg QOD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • -6.1 vs -2.9 3 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • -9.7 vs -2.9 3 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
—Not posted · NCT06588738

PASI 75

deucravacitinib
53% vs 9.4%+43.6 vs placebowk 16 · n 511NCT03611751
9 other results
  • 58.4% vs 12.7% wk 16 · n 332 · Phase 3 · primary NCT03624127
  • 68.8% vs 8.1% wk 16 · n 144 · Phase 3 · primary NCT04167462
  • 53% vs 39.8% wk 16 · n 511 · Phase 3 · secondary NCT03611751
  • 58.4% vs 35.1% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 75% vs 6.7% 12 mg QD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 66.7% vs 6.7% 6 mg BID · wk 12 · n 45 · Phase 2 · primary NCT02931838
  • 9.1% vs 6.7% 3 mg QOD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 38.6% vs 6.7% 3 mg QD · wk 12 · n 44 · Phase 2 · primary NCT02931838
  • 68.9% vs 6.7% 3 mg BID · wk 12 · n 45 · Phase 2 · primary NCT02931838
Envudeucitinib
56.4% vs 0%+56.4 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 64.1% vs 0% 40mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 33.3% vs 0% 20mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036
  • 56.4% vs 0% 20mg BID · wk 12 · n 39 · Phase 2 · primary NCT05600036
  • 19.4% vs 0% 10mg QD · wk 12 · n 36 · Phase 2 · primary NCT05600036

PASI 90

deucravacitinib
27% vs 2.7%+24.3 vs placebowk 16 · n 511NCT03611751
2 other results
  • 35.5% vs 4.2% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 38.2% vs 1.4% wk 16 · n 144 · Phase 3 · secondary NCT04167462
Envudeucitinib
—Not posted · NCT06588738

PASI 100

deucravacitinib
10.2% vs 1.2%+9 vs placebowk 16 · n 511NCT03611751
2 other results
  • 14.2% vs 0.6% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 4.2% vs 0% wk 16 · n 144 · Phase 3 · secondary NCT04167462
Envudeucitinib
—Not posted · NCT06588738

sPGA 0/1

deucravacitinib
49.5% vs 8.6%+40.9 vs placebowk 16 · n 511NCT03611751
11 other results
  • 53.6% vs 7.2% wk 16 · n 332 · Phase 3 · primary NCT03624127
  • 55.6% vs 6.8% wk 16 · n 144 · Phase 3 · primary NCT04167462
  • 49.5% vs 33.9% wk 16 · n 511 · Phase 3 · secondary NCT03611751
  • 53.6% vs 32.1% wk 16 · n 332 · Phase 3 · secondary NCT03624127
  • 75% vs 6.7% 12 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 64.4% vs 6.7% 6 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • 20.5% vs 6.7% 3 mg QOD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 38.6% vs 6.7% 3 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • 75.6% vs 6.7% 3 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • 35.5% vs 8.2% wk 16 · n 107 · Phase 4 · secondary NCT05701995
  • 51% vs 4.3% wk 16 · n 96 · Phase 4 · secondary NCT05478499
Envudeucitinib
53.8% vs 7.9%+45.9 vs placebo40mg QD · wk 12 · n 39NCT05600036
4 other results
  • 59% vs 7.9% 40mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 38.9% vs 7.9% 20mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036
  • 48.7% vs 7.9% 20mg BID · wk 12 · n 39 · Phase 2 · secondary NCT05600036
  • 16.7% vs 7.9% 10mg QD · wk 12 · n 36 · Phase 2 · secondary NCT05600036

DLQI, change

deucravacitinib
-10.2 vs -2.9−7.3 vs placebo12 mg QD · wk 12 · n 44NCT02931838
4 other results
  • -8.4 vs -2.9 6 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
  • -3.8 vs -2.9 3 mg QOD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • -6.1 vs -2.9 3 mg QD · wk 12 · n 44 · Phase 2 · secondary NCT02931838
  • -9.7 vs -2.9 3 mg BID · wk 12 · n 45 · Phase 2 · secondary NCT02931838
Envudeucitinib
—Not posted · NCT06588738
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. deucravacitinib: 4 of 4 rows · Envudeucitinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdeucravacitinibEnvudeucitinib
Dropout rate
0.2%BMS-986165a
NCT03611751 · Phase 3 · monotherapy
show 20 more results
—BMS-986165 (Week 0 up to Week 16)
NCT03611751 · Phase 3 · monotherapy
—BMS-986165 (Week 0 up to Week 52)
NCT03611751 · Phase 3 · monotherapy
0%BMS-986165
NCT03624127 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 16
NCT03624127 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 52
NCT03624127 · Phase 3 · monotherapy
9.6%Arm 1: BMS-986165
NCT04167462 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 52
NCT04167462 · Phase 3 · monotherapy
—BMS-986165 Week 16 up to Week 52
NCT04167462 · Phase 3 · monotherapy
—Active Treatment - Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
0.8%Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
—Placebo Controlled - Deucravacitin
NCT05701995 · Phase 4 · registry result, not featured evidence
—Active Treatment - Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
8.7%Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
—Placebo Controlled - Deucravacitin
NCT05478499 · Phase 4 · registry result, not featured evidence
8.1%6 mg QD
NCT03924427 · Phase 3 · registry result, not featured evidence
4.5%12 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
13.3%6 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
6.7%3 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
18.2%3 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
22.7%3 mg QOD
NCT02931838 · Phase 2 · registry result, not featured evidence
10.3%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
15.4%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
7.5%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
16.7%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—BMS-986165a
NCT03611751 · Phase 3 · monotherapy
show 20 more results
—BMS-986165 (Week 0 up to Week 16)
NCT03611751 · Phase 3 · monotherapy
—BMS-986165 (Week 0 up to Week 52)
NCT03611751 · Phase 3 · monotherapy
—BMS-986165
NCT03624127 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 16
NCT03624127 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 52
NCT03624127 · Phase 3 · monotherapy
2.7%Arm 1: BMS-986165
NCT04167462 · Phase 3 · monotherapy
—BMS-986165 Week 0 up to Week 52
NCT04167462 · Phase 3 · monotherapy
—BMS-986165 Week 16 up to Week 52
NCT04167462 · Phase 3 · monotherapy
—Active Treatment - Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
—Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
—Placebo Controlled - Deucravacitin
NCT05701995 · Phase 4 · registry result, not featured evidence
—Active Treatment - Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
3.9%Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
—Placebo Controlled - Deucravacitin
NCT05478499 · Phase 4 · registry result, not featured evidence
5.4%6 mg QD
NCT03924427 · Phase 3 · registry result, not featured evidence
2.3%12 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
6.7%6 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
2.2%3 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
4.5%3 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
2.3%3 mg QOD
NCT02931838 · Phase 2 · registry result, not featured evidence
2.6%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
2.6%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
5.6%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
0%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
Serious AEs
—BMS-986165a
NCT03611751 · Phase 3 · monotherapy
show 20 more results
1.6%BMS-986165 (Week 0 up to Week 16)
NCT03611751 · Phase 3 · monotherapy
2.9%BMS-986165 (Week 0 up to Week 52)
NCT03611751 · Phase 3 · monotherapy
—BMS-986165
NCT03624127 · Phase 3 · monotherapy
2.1%BMS-986165 Week 0 up to Week 16
NCT03624127 · Phase 3 · monotherapy
5.8%BMS-986165 Week 0 up to Week 52
NCT03624127 · Phase 3 · monotherapy
—Arm 1: BMS-986165
NCT04167462 · Phase 3 · monotherapy
2.7%BMS-986165 Week 0 up to Week 52
NCT04167462 · Phase 3 · monotherapy
0%BMS-986165 Week 16 up to Week 52
NCT04167462 · Phase 3 · monotherapy
4.9%Active Treatment - Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
—Deucravacitinib
NCT05701995 · Phase 4 · registry result, not featured evidence
2.5%Placebo Controlled - Deucravacitin
NCT05701995 · Phase 4 · registry result, not featured evidence
4.3%Active Treatment - Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
—Deucravacitinib
NCT05478499 · Phase 4 · registry result, not featured evidence
1%Placebo Controlled - Deucravacitin
NCT05478499 · Phase 4 · registry result, not featured evidence
6.8%6 mg QD
NCT03924427 · Phase 3 · registry result, not featured evidence
0%12 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
0%6 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
2.2%3 mg BID
NCT02931838 · Phase 2 · registry result, not featured evidence
2.3%3 mg QD
NCT02931838 · Phase 2 · registry result, not featured evidence
2.3%3 mg QOD
NCT02931838 · Phase 2 · registry result, not featured evidence
0%40mg BIDa
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
2.6%40mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
7.7%20mg BID
NCT05600036 · Phase 2 · registry result, not featured evidence
0%20mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
2.8%10mg QD
NCT05600036 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 10.8% (placebo 11.4%)
upper respiratory tract infection 4.9% (placebo 4.3%)
diarrhoea 4.7% (placebo 7.5%)
NCT03611751 · Phase 3 · monotherapy
show 15 more results
nasopharyngitis 16% (placebo 11.4%)
upper respiratory tract infection 8.9% (placebo 4.3%)
headache 5.4% (placebo 5.5%)
NCT03611751 · Phase 3 · monotherapy
nasopharyngitis 6.3% (placebo 4.2%)
upper respiratory tract infection 6.3% (placebo 3.6%)
headache 4.8% (placebo 3%)
NCT03624127 · Phase 3 · monotherapy
nasopharyngitis 18.1% (placebo 4.2%)
upper respiratory tract infection 9.4% (placebo 3.6%)
headache 6.6% (placebo 3%)
NCT03624127 · Phase 3 · monotherapy
upper respiratory tract infection 17.8% (placebo 18.9%)
mouth ulceration 7.5% (placebo 5.4%)
nasopharyngitis 6.8% (placebo 8.1%)
NCT04167462 · Phase 3 · monotherapy
psoriasis 11.8% (placebo 2.7%)
headache 5.9% (placebo 0%)
nasopharyngitis 5.9% (placebo 8.1%)
NCT04167462 · Phase 3 · monotherapy
covid-19 9.7% (placebo 4.1%)
upper respiratory tract infection 7.8% (placebo 2%)
nasopharyngitis 3.9% (placebo 4.1%)
NCT05701995 · Phase 4 · registry result, not featured evidence
acne 7.6% (placebo 4.1%)
nasopharyngitis 6.7% (placebo 4.1%)
covid-19 5.9% (placebo 4.1%)
NCT05701995 · Phase 4 · registry result, not featured evidence
nasopharyngitis 23.4% (placebo 17.8%)
covid-19 12.8% (placebo 8.9%)
upper respiratory tract infection 11.7% (placebo 6.7%)
NCT05478499 · Phase 4 · registry result, not featured evidence
nasopharyngitis 15.5% (placebo 17.8%)
upper respiratory tract infection 11.7% (placebo 6.7%)
acne 9.7% (placebo 2.2%)
NCT05478499 · Phase 4 · registry result, not featured evidence
6 mg QD
nasopharyngitis 31.1%
acne 9.5%
constipation 5.4%
NCT03924427 · Phase 3 · registry result, not featured evidence
12 mg QD
blood creatine phosphokinase increased 15.9% (placebo 2.2%)
acne 9.1% (placebo 0%)
diarrhoea 9.1% (placebo 4.4%)
NCT02931838 · Phase 2 · registry result, not featured evidence
6 mg BID
nasopharyngitis 15.6% (placebo 4.4%)
blood creatine phosphokinase increased 8.9% (placebo 2.2%)
upper respiratory tract infection 8.9% (placebo 2.2%)
NCT02931838 · Phase 2 · registry result, not featured evidence
3 mg BID
nasopharyngitis 11.1% (placebo 4.4%)
aphthous ulcer 6.7% (placebo 0%)
headache 6.7% (placebo 4.4%)
NCT02931838 · Phase 2 · registry result, not featured evidence
3 mg QD
nasopharyngitis 11.4% (placebo 4.4%)
headache 9.1% (placebo 4.4%)
psoriasis 6.8% (placebo 4.4%)
NCT02931838 · Phase 2 · registry result, not featured evidence
3 mg QOD
headache 9.1% (placebo 4.4%)
nausea 9.1% (placebo 4.4%)
blood immunoglobulin e increased 6.8% (placebo 2.2%)
NCT02931838 · Phase 2 · registry result, not featured evidence
40mg BIDa
headache 7.7% (placebo 5.3%)
nasopharyngitis 7.7% (placebo 7.9%)
upper respiratory tract infection 7.7% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
show 4 more results
40mg QD
headache 10.3% (placebo 5.3%)
acne 5.1% (placebo 0%)
upper respiratory tract infection 5.1% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
20mg BID
headache 7.7% (placebo 5.3%)
cough 5.1% (placebo 0%)
diarrhea 5.1% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
20mg QD
headache 5.6% (placebo 5.3%)
upper respiratory tract infection 5.6% (placebo 0%)
acne 0% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence
10mg QD
diabetes mellitus 5.6% (placebo 0%)
nasopharyngitis 5.6% (placebo 7.9%)
upper respiratory tract infection 5.6% (placebo 0%)
NCT05600036 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

deucravacitinib

PASI 90 27% (n=511) vs 2.7% (n=255) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 138 Participants as posted
show 5 more results
32.5% (n=504) vs 19.7% (n=254) Apremilast @ 24wk*
NCT03611751 · Phase 3 · monotherapy · converted to % from 164 Participants as posted
35.5% (n=332) vs 4.2% (n=166) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 118 Participants as posted
42.2% (n=332) vs 22% (n=168) Apremilast @ 24wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 140 Participants as posted
31% (n=332) vs 15.6% (n=167) Apremilast*
NCT03624127 · Phase 3 · monotherapy · converted to % from 103 Participants as posted
38.2% (n=144) vs 1.4% (n=74) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
PASI 100 10.2% (n=511) vs 1.2% (n=255) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 52 Participants as posted
show 2 more results
14.2% (n=332) vs 0.6% (n=166) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 47 Participants as posted
4.2% (n=144) vs 0% (n=74) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
sPGA (0 15.7% (n=511) vs 1.2% (n=255) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 80 Participants as posted
show 2 more results
17.5% (n=332) vs 0.6% (n=166) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 58 Participants as posted
13.9% (n=144) vs 0% (n=74) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
PSSD Symptom -28.9 vs -4.2 placebo score @ 16wk
absolute change · score
NCT03611751 · Phase 3 · monotherapy
show 2 more results
-29.4 vs -22.8 Apremilast score @ 16wk
NCT03624127 · Phase 3 · monotherapy
-29.4 vs -1.8 placebo score @ 16wk
NCT04167462 · Phase 3 · monotherapy
PSSD Symptom Score 0 7.5% (n=466) vs 1.3% (n=238) placebo @ 16wk
event count · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 35 Participants as posted
show 1 more result
7.9% (n=305) vs 0.7% (n=149) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 24 Participants as posted
Ss-PGA 0/1 59.7% (n=305) vs 17.3% (n=173) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 182 Participants as posted
show 2 more results
70.3% (n=209) vs 17.4% (n=121) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 147 Participants as posted
62.9% (n=105) vs 9.8% (n=51) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
DLQI 0/1 37.6% (n=495) vs 9.8% (n=246) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 186 Participants as posted
show 2 more results
41% (n=322) vs 10.6% (n=160) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 132 Participants as posted
36.4% (n=140) vs 11.6% (n=69) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
PGA-F 0/1 20.3% (n=69) vs 7.9% (n=38) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 14 Participants as posted
show 2 more results
20.9% (n=43) vs 8.8% (n=34) placebo @ 16wk*
NCT03624127 · Phase 3 · monotherapy · converted to % from 9 Participants as posted
19.6% (n=46) vs 4.2% (n=24) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
Pp-PGA 0/1 46.2% (n=39) vs 23.5% (n=17) placebo @ 16wk
responder rate · % of participants
NCT03611751 · Phase 3 · monotherapy · converted to % from 18 Participants as posted
show 1 more result
66.7% (n=15) vs 0% (n=7) placebo @ 16wk
NCT04167462 · Phase 3 · monotherapy
Time to Relapse Median NA vs NA placebo months
time to event · months
NCT03611751 · Phase 3 · monotherapy
PSSD Symptom Score 0 4.9% (n=142) vs 1.4% (n=73) placebo @ 16wk
responder rate · % of participants
NCT04167462 · Phase 3 · monotherapy
DLQI 0/1 33.3% (n=120) vs 6.7% (n=60) placebo @ 16wk
responder rate · % of participants
Full Analysis Set
NCT05701995 · Phase 4 · registry result, not featured evidence

+ 9 further endpoints in the CSV export.

Systemic Lupus Erythematosus

Shared mechanism: TYK2 · full Systemic Lupus Erythematosus pipeline

deucravacitinib · Sotyktu

Marketed by Bristol-Myers Squibb

Phase 3 in Systemic Lupus Erythematosussmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2028 · NCT06875960 (registry estimate)

No aligned efficacy figure on record for this race.

Envudeucitinib

Developed by Alumis and partners

Phase 2 in Systemic Lupus Erythematosussmall molecule
Partial signal

NCT05966480 · Phase 2 · active, not recruiting

The trial was well designed -- randomized, triple-blinded, placebo-controlled, and adequately sized (n=408) with a recognized disease-activity measure (BICLA) as its primary endpoint -- but the overall primary comparison did not reach statistical significance. A positive signal in one prespecified subgroup does not change the fact that the main, prespecified population analysis missed, so this remains solid but inconclusive evidence rather than strong evidence of a benefit.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

To compare the effect on disease activity measured by the proportion of patients achieving British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) response at Week 48 between doses of ESK-001 and placebo: LUMUS trial (NCT05966480), primary endpoint BICLA response: envudeucitinib did not meet its primary endpoint in the overall trial population, but a prespecified IFNGS-high subgroup showed robust clinical responses on the same primary endpoint (BICLA). (missed)

Result source: NCT05966480

Results for Systemic Lupus Erythematosus

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointdeucravacitinibEnvudeucitinib
SRI-444.9% vs 34.4%+10.5 vs placebo12 mg · wk 32 · n 89NCT03252587
5 other results
  • 49.5% vs 34.4% 6 mg · wk 32 · n 93 · Phase 2 · primary NCT03252587
  • 58.2% vs 34.4% 3 mg · wk 32 · n 91 · Phase 2 · primary NCT03252587
  • 47.2% vs 34.4% 12 mg · wk 48 · n 89 · Phase 2 · secondary NCT03252587
  • 47.3% vs 34.4% 6 mg · wk 48 · n 93 · Phase 2 · secondary NCT03252587
  • 57.1% vs 34.4% 3 mg · wk 48 · n 91 · Phase 2 · secondary NCT03252587
—Not reported
BICLA36% vs 25.6%+10.4 vs placebo12 mg · wk 48 · n 89NCT03252587
2 other results
  • 35.5% vs 25.6% 6 mg · wk 48 · n 93 · Phase 2 · secondary NCT03252587
  • 47.3% vs 25.6% 3 mg · wk 48 · n 91 · Phase 2 · secondary NCT03252587
—Not reported
CLASI-5062.1% vs 16.7%+45.4 vs placebo12 mg · wk 48 · n 29NCT03252587
2 other results
  • 56% vs 16.7% 6 mg · wk 48 · n 25 · Phase 2 · secondary NCT03252587
  • 69.6% vs 16.7% 3 mg · wk 48 · n 23 · Phase 2 · secondary NCT03252587
—Not reported
Steroid sparing—Trial running · NCT05620407—Not reported

SRI-4

deucravacitinib
44.9% vs 34.4%+10.5 vs placebo12 mg · wk 32 · n 89NCT03252587
5 other results
  • 49.5% vs 34.4% 6 mg · wk 32 · n 93 · Phase 2 · primary NCT03252587
  • 58.2% vs 34.4% 3 mg · wk 32 · n 91 · Phase 2 · primary NCT03252587
  • 47.2% vs 34.4% 12 mg · wk 48 · n 89 · Phase 2 · secondary NCT03252587
  • 47.3% vs 34.4% 6 mg · wk 48 · n 93 · Phase 2 · secondary NCT03252587
  • 57.1% vs 34.4% 3 mg · wk 48 · n 91 · Phase 2 · secondary NCT03252587
Envudeucitinib
—Not reported

BICLA

deucravacitinib
36% vs 25.6%+10.4 vs placebo12 mg · wk 48 · n 89NCT03252587
2 other results
  • 35.5% vs 25.6% 6 mg · wk 48 · n 93 · Phase 2 · secondary NCT03252587
  • 47.3% vs 25.6% 3 mg · wk 48 · n 91 · Phase 2 · secondary NCT03252587
Envudeucitinib
—Not reported

CLASI-50

deucravacitinib
62.1% vs 16.7%+45.4 vs placebo12 mg · wk 48 · n 29NCT03252587
2 other results
  • 56% vs 16.7% 6 mg · wk 48 · n 25 · Phase 2 · secondary NCT03252587
  • 69.6% vs 16.7% 3 mg · wk 48 · n 23 · Phase 2 · secondary NCT03252587
Envudeucitinib
—Not reported

Steroid sparing

deucravacitinib
—Trial running · NCT05620407
Envudeucitinib
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Envudeucitinib
LUMUS trial (NCT05966480), primary endpoint BICLA response: envudeucitinib did not meet its primary endpoint in the overall trial population, but a prespecified IFNGS-high subgroup showed robust clinical responses on the same primary endpoint (BICLA). NCT05966480 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. deucravacitinib: 4 of 4 rows · Envudeucitinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricdeucravacitinib
Dropout rate
39.7%12mg QDa
NCT03920267 · Phase 2 · registry result, not featured evidence
show 8 more results
61.9%12mg QD
NCT03920267 · Phase 2 · registry result, not featured evidence
39.7%6mg BID
NCT03920267 · Phase 2 · registry result, not featured evidence
38.1%6mg BID
NCT03920267 · Phase 2 · registry result, not featured evidence
37.3%3mg BID
NCT03920267 · Phase 2 · registry result, not featured evidence
57.1%3mg BID
NCT03920267 · Phase 2 · registry result, not featured evidence
30.3%12 mg
NCT03252587 · Phase 2 · registry result, not featured evidence
18.3%6 mg
NCT03252587 · Phase 2 · registry result, not featured evidence
22%3 mg
NCT03252587 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
8.6%12mg QDa
NCT03920267 · Phase 2 · registry result, not featured evidence
show 8 more results
9.5%12mg QD
NCT03920267 · Phase 2 · registry result, not featured evidence
9.6%6mg BID
NCT03920267 · Phase 2 · registry result, not featured evidence
0%6mg BID
NCT03920267 · Phase 2 · registry result, not featured evidence
6%3mg BID
NCT03920267 · Phase 2 · registry result, not featured evidence
14.3%3mg BID
NCT03920267 · Phase 2 · registry result, not featured evidence
13.5%12 mg
NCT03252587 · Phase 2 · registry result, not featured evidence
6.5%6 mg
NCT03252587 · Phase 2 · registry result, not featured evidence
8.8%3 mg
NCT03252587 · Phase 2 · registry result, not featured evidence
Serious AEs
22.4%12mg QDa
NCT03920267 · Phase 2 · registry result, not featured evidence
show 8 more results
19%12mg QD
NCT03920267 · Phase 2 · registry result, not featured evidence
12.3%6mg BID
NCT03920267 · Phase 2 · registry result, not featured evidence
0%6mg BID
NCT03920267 · Phase 2 · registry result, not featured evidence
16.4%3mg BID
NCT03920267 · Phase 2 · registry result, not featured evidence
14.3%3mg BID
NCT03920267 · Phase 2 · registry result, not featured evidence
7.9%12 mg
NCT03252587 · Phase 2 · registry result, not featured evidence
8.6%6 mg
NCT03252587 · Phase 2 · registry result, not featured evidence
7.7%3 mg
NCT03252587 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
12mg QDa
covid-19 27.6%
nasopharyngitis 22.4%
upper respiratory tract infection 19%
NCT03920267 · Phase 2 · registry result, not featured evidence
show 8 more results
12mg QD
covid-19 19%
nasopharyngitis 19%
acne 14.3%
NCT03920267 · Phase 2 · registry result, not featured evidence
6mg BID
covid-19 28.8%
urinary tract infection 21.9%
upper respiratory tract infection 15.1%
NCT03920267 · Phase 2 · registry result, not featured evidence
6mg BID
nasopharyngitis 23.8%
covid-19 19%
diarrhoea 19%
NCT03920267 · Phase 2 · registry result, not featured evidence
3mg BID
covid-19 35.8%
nasopharyngitis 19.4%
upper respiratory tract infection 19.4%
NCT03920267 · Phase 2 · registry result, not featured evidence
3mg BID
covid-19 23.8%
urinary tract infection 14.3%
acne 9.5%
NCT03920267 · Phase 2 · registry result, not featured evidence
12 mg
headache 12.4% (placebo 16.7%)
nasopharyngitis 9% (placebo 12.2%)
upper respiratory tract infection 9% (placebo 8.9%)
NCT03252587 · Phase 2 · registry result, not featured evidence
6 mg
upper respiratory tract infection 19.4% (placebo 8.9%)
nasopharyngitis 14% (placebo 12.2%)
acne 8.6% (placebo 4.4%)
NCT03252587 · Phase 2 · registry result, not featured evidence
3 mg
upper respiratory tract infection 14.3% (placebo 8.9%)
urinary tract infection 11% (placebo 3.3%)
nasopharyngitis 8.8% (placebo 12.2%)
NCT03252587 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

deucravacitinib

SRI-4 44.9% (n=89) vs 34.4% (n=90) placebo @ 32wk12 mg
responder rate · % of participants
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 40 Participants as posted
show 5 more results
47.2% (n=89) vs 34.4% (n=90) placebo @ 48wk*12 mg
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 42 Participants as posted
49.5% (n=93) vs 34.4% (n=90) placebo @ 32wk*6 mg
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 46 Participants as posted
47.3% (n=93) vs 34.4% (n=90) placebo @ 48wk*6 mg
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 44 Participants as posted
58.2% (n=91) vs 34.4% (n=90) placebo @ 32wk*3 mg
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 53 Participants as posted
57.1% (n=91) vs 34.4% (n=90) placebo @ 48wk*3 mg
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 52 Participants as posted
BICLA 36% (n=89) vs 25.6% (n=90) placebo @ 48wk12 mg
responder rate · % of participants
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted
show 2 more results
35.5% (n=93) vs 25.6% (n=90) placebo @ 48wk*6 mg
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted
47.3% (n=91) vs 25.6% (n=90) placebo @ 48wk*3 mg
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 43 Participants as posted
LLDAS 25.8% (n=89) vs 13.3% (n=90) placebo @ 48wk12 mg
event count · % of participants
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 23 Participants as posted
show 2 more results
23.7% (n=93) vs 13.3% (n=90) placebo @ 48wk*6 mg
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
36.3% (n=91) vs 13.3% (n=90) placebo @ 48wk*3 mg
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted
CLASI-50 62.1% (n=29) vs 16.7% (n=24) placebo @ 48wk12 mg
responder rate · % of participants
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 18 Participants as posted
show 2 more results
56% (n=25) vs 16.7% (n=24) placebo @ 48wk*6 mg
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
69.6% (n=23) vs 16.7% (n=24) placebo @ 48wk*3 mg
NCT03252587 · Phase 2 · registry result, not featured evidence · converted to % from 16 Participants as posted
Tender Joint Count -12.3 vs -11.2 placebo score @ 48wk12 mg
absolute change · score
Tender
NCT03252587 · Phase 2 · registry result, not featured evidence
show 2 more results
-11.7 vs -11.2 placebo score @ 48wk6 mg
Tender
NCT03252587 · Phase 2 · registry result, not featured evidence
-12.2 vs -11.2 placebo score @ 48wk3 mg
Tender
NCT03252587 · Phase 2 · registry result, not featured evidence
Swollen Joint Count -9.9 vs -8.3 placebo score @ 48wk12 mg
absolute change · score
Swollen
NCT03252587 · Phase 2 · registry result, not featured evidence
show 2 more results
-8.8 vs -8.3 placebo score @ 48wk6 mg
Swollen
NCT03252587 · Phase 2 · registry result, not featured evidence
-8.5 vs -8.3 placebo score @ 48wk3 mg
Swollen
NCT03252587 · Phase 2 · registry result, not featured evidence
Active Joint Count -9.7 vs -8.2 placebo score @ 48wk12 mg
absolute change · score
Tender + Swollen
NCT03252587 · Phase 2 · registry result, not featured evidence
show 2 more results
-8.5 vs -8.2 placebo score @ 48wk6 mg
Tender + Swollen
NCT03252587 · Phase 2 · registry result, not featured evidence
-8.2 vs -8.2 placebo score @ 48wk3 mg
Tender + Swollen
NCT03252587 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: deucravacitinib's landscape · Envudeucitinib's landscape